TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04998513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical Management Alone Arm
Description: The medical intervention consists of intravenous dexamethasone (10 mg if bodyweight \< 70 kilograms, 20 mg if bodyweight \> 70 kilograms), intravenous cefazolin 2 grams, intravenous metronidazole 500 mg, oral probenecid 2 grams, and 1 liter of intravenous crystalloid fluid given over 1 hour.~If, during the initial post-enrolment day 1 follow-up, patients report a failure of signs and symptoms to improve since their medical therapy, a second round of intravenous crystalloid fluid, cefazolin, probenecid, metronidazole and dexamethasone will be given at the same dose as the initial medical therapy. Failure to improve patient signs and symptoms over a two-hour observation window will prompt surgical intervention to be performed in the same fashion as the surgical intervention group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Arm
Description: Surgical intervention consists of attempted incision and drainage of the abscess. Specific procedure steps and details are at the discretion of the treating surgeon. In general, incision and drainage consists of topical and submucosal local anesthetic followed by a mucosal incision along the palatoglossal arch and soft palate junction, and blunt dissection of the abscess cavity to evacuate pus. Some surgeons may first perform a needle aspiration. For purposes of the trial, positive aspiration of pus on needle aspiration must be followed by attempted incision and drainage. Failed needle aspiration or surgical drainage will be considered as a failed attempt at surgical intervention.~Patients randomized to receive surgical intervention will also receive medications as per the medical management arm.
Study: NCT06560788

Intervention type: OTHER
Intervention: collection of cerebrospinal fluid
Description: CSF is collected as part of routine care in any of the surgeries listed in the control or cases groups. We will take part of that CSF for proteomic analysis
Study: NCT05485779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQ280
Description: Dose form: capsule, hard~Strength: 3 to 100 mg~Method of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQ280
Description: Dose form: capsule, hard~Strength: 3 to 100 mg~Method of administration: oral
Study: NCT06560788

Intervention type: OTHER
Intervention: collection of cerebrospinal fluid
Description: CSF is collected as part of routine care in any of the surgeries listed in the control or cases groups. We will take part of that CSF for proteomic analysis

Intervention type: OTHER
Intervention: collection of cerebrospinal fluid
Description: CSF is collected as part of routine care in any of the surgeries listed in the control or cases groups. We will take part of that CSF for proteomic analysis

Intervention type: OTHER
Intervention: collection of cerebrospinal fluid
Description: CSF is collected as part of routine care in any of the surgeries listed in the control or cases groups. We will take part of that CSF for proteomic analysis

Intervention type: OTHER
Intervention: collection of cerebrospinal fluid
Description: CSF is collected as part of routine care in any of the surgeries listed in the control or cases groups. We will take part of that CSF for proteomic analysis
Study: NCT05485779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQ280
Description: Dose form: capsule, hard~Strength: 3 to 100 mg~Method of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Active substance: none~Dose form: capsule, hard~Strength/dose: not applicable~Method of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Active substance: none~Dose form: capsule, hard~Strength/dose: not applicable~Method of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Active substance: none~Dose form: capsule, hard~Strength/dose: not applicable~Method of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Active substance: none~Dose form: capsule, hard~Strength/dose: not applicable~Method of administration: oral
Study: NCT06560788

Intervention type: OTHER
Intervention: collection of cerebrospinal fluid
Description: CSF is collected as part of routine care in any of the surgeries listed in the control or cases groups. We will take part of that CSF for proteomic analysis

Intervention type: OTHER
Intervention: collection of cerebrospinal fluid
Description: CSF is collected as part of routine care in any of the surgeries listed in the control or cases groups. We will take part of that CSF for proteomic analysis
Study: NCT04868565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine Citrate 20 MG/1 ML Intravenous Solution [CAFCIT]
Description: after randomization, caffeine citrate will be contineously prescribed to those patients assigned to the ongoing caffeine with oxygen supplement (group 2) with a medication regimen of 10mg/kg.dose, once daily, and weekly adjustment based on the working weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine Citrate 20 MG/1 ML Intravenous Solution [CAFCIT]
Description: after randomization, caffeine citrate will be contineously prescribed to those patients assigned to the ongoing caffeine with oxygen supplement (group 2) with a medication regimen of 10mg/kg.dose, once daily, and weekly adjustment based on the working weight.
Study: NCT04742075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib + durvalumab + UV1
Description: The subjects are randomized 1:1:2 to receive treatment until progression of disease or untorable toxicity.
Study: NCT04878237

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Secretion Sampling
Description: Nasal specimen collection will be performed at all visits. For every visit specimens will be collected using nasosorption FXi/PU (containing a synthetic absorptive matrix (SAM)), or a 10 cm-long plastic curette (nasosorption devices from Hunt Developments, UK) (Curette devices from Arlington Scientific, USA)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Secretion Sampling
Description: Nasal specimen collection will be performed at all visits. For every visit specimens will be collected using nasosorption FXi/PU (containing a synthetic absorptive matrix (SAM)), or a 10 cm-long plastic curette (nasosorption devices from Hunt Developments, UK) (Curette devices from Arlington Scientific, USA)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nasal Secretion Sampling
Description: Nasal specimen collection will be performed at all visits. For every visit specimens will be collected using nasosorption FXi/PU (containing a synthetic absorptive matrix (SAM)), or a 10 cm-long plastic curette (nasosorption devices from Hunt Developments, UK) (Curette devices from Arlington Scientific, USA)
Study: NCT04917627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: one vial of vancomycin (1000 mg ) powder form.
Study: NCT05654194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine Combined With Venetoclax and ATRA group
Description: AZA 75mg/m² per day for days 1-7 and venetoclax 100mg orally for day 2 , 200mg orally for day 3, 300mg orally for day4-6, 400mg orally for day7-10,ATRA 45mg/m² for day 12-28,every 28 days for up to 2 cycles as the inductive therapy.ATRA 45mg/m2 per day for d1-21 ,AZA 70mg/m² per day for days 1-7, every 28 days for up to 4 cycles for consolidate therapy.ATRA 45mg/m2 for d1-21 every 28 days,AZA 70mg/m² per day for days 1-7, every 3 month for Maintenance therapy
Study: NCT04742075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib + durvalumab + UV1
Description: The subjects are randomized 1:1:2 to receive treatment until progression of disease or untorable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib + durvalumab + UV1
Description: The subjects are randomized 1:1:2 to receive treatment until progression of disease or untorable toxicity.
Study: NCT05085782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride
Description: 6 weekly doses (40 to 80 mg) 1h before the reactivation procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 weekly doses (40 to 80 mg) 1h before the reactivation procedure

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Reactivation procedure
Description: Description/visualization of painful movements/activities

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reactivation procedure
Description: Description/visualization of painful movements/activities
Study: NCT04789083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propholis extrate
Description: Plassebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propholis extrate
Description: Plassebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Propholis extrate
Description: Plassebo
Study: NCT05085782

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Pain neuroscience education
Description: In the form of 10 videos that participants will watch on their own time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education
Description: In the form of 10 videos that participants will watch on their own time
Study: NCT06400303

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KYV-101
Description: Anti-CD19 CAR-T cell therapy
Study: NCT05505305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating and high-intensity interval training
Description: Maximal daily eating window of 10 hours and high-intensity interval training (three weekly, unsupervised, aerobic exercise sessions performed at \> 90 % heart rate maximum). Each exercise session will last for 33-38 minutes. Participants will receive digital follow-up once weekly. The intervention period will be seven weeks,
Study: NCT05112718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma Injections
Description: PRP injected into 9 sites of the distal anterior one-third of the vagina using a small 30-gauge needle. The injections were performed at 10, 12 and 2 o'clock in 3 different levels of the urethra 1-2 cm apart (distal, mid and proximal).~The participants will receive 2 PRP injections at 4-6-week intervals. Xylocaine gel 2% is applied to the distal anterior vaginal wall 20 minutes before injections.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normal Saline Injections
Description: Normal saline injected into 9 sites of the distal anterior one-third of the vagina using a small 30-gauge needle. The injections were performed at 10, 12 and 2 o'clock in 3 different levels of the urethra 1-2 cm apart (distal, mid and proximal).~The participants will receive 2 injections at 4-6-week intervals.
Study: NCT05549297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebentafusp
Description: Soluble gp100-specific T cell receptor with anti-CD3 scFV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebentafusp with Pembrolizumab
Description: Soluble gp100-specific T cell receptor with anti-CD3 scFV in combination with pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigators Choice
Description: Investigators choice of therapy
Study: NCT05481411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olpasiran
Description: Subcutaneous injection
Study: NCT05485779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Active substance: none~Dose form: capsule, hard~Strength/dose: not applicable~Method of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Active substance: none~Dose form: capsule, hard~Strength/dose: not applicable~Method of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Active substance: none~Dose form: capsule, hard~Strength/dose: not applicable~Method of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Active substance: none~Dose form: capsule, hard~Strength/dose: not applicable~Method of administration: oral
Study: NCT04989829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390、Omeprazole
Description: SHR6390 tablet single dose、Omeprazol single dose.
Study: NCT04770610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT-101 Ophthalmic Solution
Description: Atropine 0.01%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT-101 Ophthalmic Solution
Description: Atropine 0.01%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Investigational Product minus active ingredient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Investigational Product minus active ingredient
Study: NCT06400303

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KYV-101
Description: Anti-CD19 CAR-T cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard lymphodepletion regimen
Description: Standard lymphodepletion regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard lymphodepletion regimen
Description: Standard lymphodepletion regimen
Study: NCT05206370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisinicline
Description: film-coated oral tablets containing 3 mg cytisinicline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisinicline
Description: film-coated oral tablets containing 3 mg cytisinicline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: film-coated oral tablets containing matched placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: film-coated oral tablets containing matched placebo

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral support
Description: Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral support
Description: Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral support
Description: Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.
Study: NCT06419868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Universal preventive intervention for depression and anxiety for university students
Description: This is a self-applied online intervention with six modules. It should be implemented over a period of 4 to 8 weeks. It includes emotion regulation, mindfulness exercises, coping strategies, problem-solving strategies, psychoeducation of anxiety and depression, and the development of healthy behaviors, explained through the following theoretical components: mindfulness and cognitive behavioral therapy.~Participants will be guided through the program in a structured manner. They will start by accessing the CANVAS online platform, where they will find the content of the sessions in video, audio, and text formats. They will then be directed to practice exercises at home, with audiovisual material to guide them. It's crucial that participants complete the six sessions sequentially, as each session is designed to build upon the previous one, ensuring a comprehensive learning experience and effective learning.
Study: NCT06287801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Annual Wellness Visit
Description: Completion of a structured Annual Wellness Visit (AWV) questionnaire administered by an assigned practice staff member for Medicare beneficiaries deemed by study algorithm as high-risk. Those responses will then be used by the primary care team to place any needed referrals and offer any indicated personal health advice and create a care plan for the coming year. Routine usual care from the primary care practice will occur.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Annual Wellness Visit
Description: Completion of a structured Annual Wellness Visit (AWV) questionnaire administered by an assigned practice staff member for Medicare beneficiaries deemed by study algorithm as high-risk. Those responses will then be used by the primary care team to place any needed referrals and offer any indicated personal health advice and create a care plan for the coming year. Routine usual care from the primary care practice will occur.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric Resources and Assessment for the Care of Elders
Description: The practice will initiate the Geriatric Resources and Assessment for the Care of Elders (GRACE) program for Medicare beneficiaries deemed by study algorithm as high-risk and meeting other study criteria (see below). After completion of the in-home structured annual wellness visit (AWV) and GRACE assessment by the NP/SW team, responses will be reviewed and applied to construct an individualized care plan using the GRACE protocols inclusive of advance care planning, health maintenance, medication management, assistance with any difficulty walking, falls, dementia, depression, chronic pain, malnutrition, weight loss, urinary incontinence, visual impairment, hearing impairment, or caregiver burden.
Study: NCT05161481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avenciguat (BI 685509)
Description: Avenciguat (BI 685509)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avenciguat (BI 685509)
Description: Avenciguat (BI 685509)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Avenciguat (BI 685509)
Description: Placebo matching Avenciguat (BI 685509)
Study: NCT05634811

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA15
Description: 6-valent OspA-based Lyme disease vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% sodium chloride solution for injection
Study: NCT06099665

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated alert
Description: Receiving an automated alert via the EHR to highlight that the patient in question presents for severe aortic stenosis or severe mitral regurgitation according to the AHA guidelines and that they are a good candidate for valve intervention. The alert will not list any specific manufacturer's device.
Study: NCT06469021

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Approach
Description: Structured scoliosis exercises will be prescribed by the physiotherapist according to the severity of the curvature and cosmetics of the individuals. In a one session period, 5-minute warm-up and cool-down periods, 20 minutes of scoliosis exercises, 10 minutes of core stabilization exercises and 10 minutes of balance training will be applied. The exercises will start from an easy level and the level of difficulty will be gradually increased. The assessments will be evaluated in three stages: at the beginning of treatment, at the third month of treatment and at the end of treatment (sixth month).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitative Game Therapy
Description: Structured scoliosis exercises will be prescribed by the physiotherapist according to the severity of the curvature and cosmetics of the patients and will be applied to the patients with a conventional approach. In a one-session period, 5-minute warm-up and cool-down periods, 20 minutes of scoliosis exercises, 10 minutes of core stabilization exercises, and 10 minutes of balance training will be applied in the clinical setting. Home exercises will be performing with the SmartPose system differently from the control group. The SmartPose system is a special software system that enables the user to perform movements with a tablet or phone without the need for any sensors.
Study: NCT06264596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: The epinephrine group will have two 3-L normal saline solution bags prepared for each case with 1 mL of 1:1000 epinephrine in each bag

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal Saline irrigation fluid
Description: The control group will have two 3-L normal saline solution bags prepared with no additive

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline irrigation fluid
Description: The control group will have two 3-L normal saline solution bags prepared with no additive
Study: NCT05308004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Care Consultation
Description: Trained provider will discuss illness trajectories, establish and communicate patient-directed goals that guide health care decisions, identify and treat illness-related symptoms, and identify psycho-spiritual needs and approaches to mitigate suffering
Study: NCT05206929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self Managed Care
Description: Self Managed Care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self Managed Care
Description: Self Managed Care
Study: NCT06381102

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous auricular vagus nerve stimulation 30/30
Description: Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a 30 second on and 30 second off, for 1 hour, in-person.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous auricular vagus nerve stimulation 30/30
Description: Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a 30 second on and 30 second off, for 1 hour, in-person.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous auricular vagus nerve stimulation 10/10
Description: Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a 10 second on and 10 second off, for 1 hour, in-person.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous auricular vagus nerve stimulation 10/10
Description: Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a 10 second on and 10 second off, for 1 hour, in-person.